Open Label Extension in Adults With Binge Eating Disorder (BED)

Completed · Phase 3

Conditions studied: Binge Eating Disorder

In brief

To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults

Key facts

Study ID
NCT01657019
Run by
Shire
People needed
604
Starts
2012-08-21
Expected to finish
2014-10-21
Last updated by the study team
2021-06-09

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.